In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.
This case follows a 35-year-old man with polycythemia vera from presentation in the ED through initiating and modifying treatment with phlebotomy and hydroxyurea, and eventually achieving optimal management of symptoms and CBC with ruxolitinib.
Researchers assessed outcomes for 587 patients with PV to determine the risk factors most likely to predict arterial or venous thrombosis in this patient population.
Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.
This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.
Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.
Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.
Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.
Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.
This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.
The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.
Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.
High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.
Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss.
Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).
Drug is approved for patients who cannot tolerate or have an inadequate response to other meds.
Sign Up for Free e-newsletters
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- FDA Approves HPV Vaccine for People Through Age 45
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Strength and Hope for Women in the Mist of Cancer
- Prospective Study Measures Cognitive, Treatment Effects in Older Breast Cancer Survivors
- Immune Checkpoint Inhibitor Therapy May Affect Thyroid Function
- Hypofractionated Radiotherapy After Conservative Surgery May Increase Low-intermediate Grade Late Fibrosis in Breast Cancer Patients
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|